基于美国炎症性肠病前瞻性成人研究队列的治疗达标监测结肠镜在治疗启动后的使用情况
研究评估SPARC IBD队列中启动新生物制剂或托法替布治疗后3-15个月内接受结肠镜监测的比例,1708例启动中49.3%(95%CI 46.2%-52.5%)接受了结肠镜,各中心使用率从26.6%到63.2%不等,提示真实世界中治疗达标监测结肠镜使用率较低且中心间差异大。
要点
- 启动新IBD治疗后3-15个月内49.3%(95%CI 46.2%-52.5%)接受了结肠镜监测。
- 男性、40岁以上及启动后3个月内已行结肠镜者结肠镜使用率更高。
- 各研究中心结肠镜使用率从26.6%(15.0%-38.3%)到63.2%(54.5%-72.0%)不等。
核心结论
- 约半数SPARC IBD患者在启动新IBD治疗后3-15个月内接受结肠镜,提示真实临床实践中治疗达标监测结肠镜评估黏膜愈合的使用率较低。
- 各研究中心结肠镜使用率的差异提示缺乏共识,需要更有力的证据明确常规监测结肠镜是否与患者结局改善相关。
研究设计与样本
- 研究为基于SPARC IBD前瞻性成人研究队列的分析,纳入2017年至2022年间启动新生物制剂(英夫利西单抗、阿达木单抗、培塞利珠单抗、戈利木单抗、维得利珠单抗和乌司奴单抗)或托法替布的1708例合格启动。
主要发现
- 在1708例启动中,最常用药物为乌司奴单抗(32%)、英夫利西单抗(22%)、维得利珠单抗(20%)和阿达木单抗(16%)。
- 患者中位年龄38岁,66%为克罗恩病,55%为女性,12%为非白人。
- 启动药物后3-15个月内,49.3%(95%CI 46.2%-52.5%)的启动后续接受了结肠镜检查。
- 结肠镜使用在溃疡性结肠炎与克罗恩病之间相似,但在男性、40岁以上及启动后3个月内接受结肠镜的患者中更高。
- 各研究中心结肠镜使用率从26.6%(95%CI 15.0%-38.3%)到63.2%(95%CI 54.5%-72.0%)不等。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Endoscopic healing has been associated with improved long-term clinical outcomes in inflammatory bowel disease (IBD) and is a recommended target for treatment. Evidence is limited regarding real-world uptake and patterns of treat-to-target monitoring to assess endoscopic healing after treatment initiation. We aimed to estimate the proportion of patients in the Study of a Prospective Adult Research Cohort with IBD (SPARC IBD) who received colonoscopy in the 3-15 months after starting a new IBD treatment. METHODS: We identified SPARC IBD patients who initiated a new biologic (infliximab, adalimumab, certolizumab pegol, golimumab, vedolizumab, and ustekinumab) or tofacitinib. We estimated the proportion of patients who received colonoscopies in the 3-15 months after IBD treatment initiation and described use by patient subgroups. RESULTS: Among 1,708 eligible initiations from 2017 to 2022, the most common medications were ustekinumab (32%), infliximab (22%), vedolizumab (20%), and adalimumab (16%). The median patient age was 38 years, with 66% Crohn's disease; 55% were female, and 12% were non-White. In the 3-15 months after medication initiation, 49.3% (95% confidence interval 46.2%-52.5%) of initiations were followed by a colonoscopy. Colonoscopy use was similar between ulcerative colitis and Crohn's disease, but was higher among male patients, those older than 40 years, and those who received colonoscopy within 3 months of initiation. Colonoscopy use varied between study sites, from 26.6% (15.0%-38.3%) to 63.2% (54.5%-72.0%). DISCUSSION: Approximately half of SPARC IBD patients received colonoscopy in the 3-15 months after initiation to a new IBD treatment, suggesting a low uptake of treat-to-target colonoscopy for the assessment of mucosal healing in real-world clinical practice. The variation in colonoscopy use between study sites suggests a lack of consensus and a need for more robust evidence around whether or not the practice of routine monitoring colonoscopy is associated with improved patient outcomes.
引用
- Yang JY, Lund JL, Funk MJ, et al. Utilization of Treat-to-Target Monitoring Colonoscopy After Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease. Am J Gastroenterol. 2023. PMID: 37053548. doi:10.14309/ajg.0000000000002294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。